AVON FOUNDATION SUPPORTS PREEMPTIVE CARE FOR LYMPHOEDEMA

NOT FOR DISTRIBUTION OR RELEASE IN THE UNITED STATES OR TO U.S. PERSONS

Brisbane, Australia – ImpediMed Limited (ASX:IPD) (the Group or the Company) is pleased to report the Avon Foundation for Women today issued a U.S. national press release announcing the publication of a white paper addressing lymphoedema in breast cancer patients.

In April of this year, Avon Foundation for Women, in partnership with the National Lymphedema Network and the Lymphatic Research Foundation, held an expert panel ‘think tank’ meeting to discuss recent developments in breast cancer related lymphoedema. The white paper was written by the faculty made up of nationally recognized lymphoedema experts, physicians and advocates. Early detection and intervention of sub-clinical lymphoedema plays an important role in the panel’s recommendations and call-to-action.

“The Avon Foundation for Women has been an outspoken national advocate of issues affecting women, particularly breast cancer”, said Greg Brown, ImpediMed’s CEO. “We applaud their leadership in addressing lymphoedema management as a vital quality-of-life issue affecting so many breast cancer patients. Avon has played an active role in the education of physicians and patients regarding lymphoedema risk. As a leading breast cancer advocacy organization within the United States, we appreciate their support and recognition of new technologies such as L-Dex®.”

The full version white paper, as well as a summary and its call-to-action can be accessed under Programs and Events on the Avon Foundation website:


This white paper is important to the Company as it is the first U.S. national breast cancer advocate group putting lymphoedema and its preemptive management on the U.S. healthcare agenda. ImpediMed’s U400 L-Dex device aids in the clinical assessment of lymphoedema in women through the measurement of extracellular fluid differences of the arms. Extracellular fluid differences in the arms are recognised, through the literature, as the earliest marker of change within the pathophysiology of lymphoedema.

Greg Brown
CEO

ENDS
For further information contact:
Greg Brown
ImpediMed CEO
T: 61-7-3860-3700
Mobile/Cell: +61408281127

L-Dex™ is a trademark of ImpediMed Limited.

The L-Dex scale is a tool to assist in the clinical assessment of lymphoedema by a medical provider. The L-Dex scale is not intended to diagnose or predict lymphoedema of an extremity.

L-Dex™ values that have an increase of ten (10) L-Dex units from a patient’s baseline L-Dex value represent a change of three (3) standard deviations (3SD). This has been demonstrated in a matched normal population to be potentially clinically relevant to the medical provider in aiding in the clinical assessment of unilateral lymphoedema of the arm. For an initial assessment where no measurement history exists, a range representing 3SD either side of a normal population mean is highlighted on the L-Dex scale to aid the medical provider in their clinical assessment. Medical providers need to be aware that a 3SD change can still occur within this range and where possible should utilize changes from baseline of 10 L-Dex units.

About ImpediMed
ImpediMed Ltd. is the world leader in the development and distribution of medical devices employing Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of fluid status. ImpediMed’s primary product range consists of a number of medical devices that aid surgeons, oncologists, therapists and radiation oncologists in the clinical assessment of patients for the potential onset of secondary lymphoedema. Pre-operative clinical assessment in breast cancer survivors, before the onset of symptoms, may prevent the condition from becoming a lifelong management issue and thus improve the quality of life of the cancer survivor. ImpediMed has the first medical device with an FDA clearance in the United States to aid health care professionals, clinically assess secondary lymphoedema of the arm in female breast cancer patients.

For more information, visit: www.impedimed.com.

Avon Foundation for Women
The Avon Foundation for Women, the world’s largest corporate-affiliated philanthropy focused on issues that matter most to women, was founded in 1955 to improve the lives of women. Through 2010, Avon global philanthropy has donated more than $800 million in more than 50 countries for causes most important to women. Today, Avon philanthropy focuses its funding on breast cancer research and access to care through the Avon Breast Cancer Crusade, and efforts to reduce domestic and gender violence through its Speak Out Against Domestic Violence program. Avon also responds generously to provide support for relief and recovery efforts in times of major natural disasters and emergencies.

For more information, visit: www.avonfoundation.org.